Plain-English translation of NCT07040566 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called varenicline can help people who vape daily quit e-cigarettes for good. You would receive either the medication or a placebo (a fake pill that looks identical) along with counseling support to help you stop vaping. The researchers will track your progress over several months to see if the medication works better than placebo at helping people quit.
Vaping is a growing public health concern, especially nicotine addiction from e-cigarettes. Right now, there aren't many proven treatments specifically designed to help people quit vaping, so researchers are testing whether this medication—which has helped some people quit traditional cigarettes—might also work for e-cigarette users.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the medication or a placebo pill for 12 weeks, along with brief counseling sessions and self-help resources to support your quit attempt. You'll visit the study site every 3 weeks during the treatment phase to check in, answer questions about your vaping, and provide samples for health testing. After the 12-week treatment ends, you'll return for one final visit at week 26 so researchers can see how well the treatment worked.
AI-generated summary from trial data · Sep 11, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Yale University
Collaborators
National Cancer Institute (NCI)
Enrollment target
~326 participants
Started
October 2025
Primary completion
July 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lisa Fucito, PhD
Yale University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.